BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...to submit an NDA in China for the antibody derived from the OmniAb platform from Ligand Pharmaceuticals Inc....
BioCentury | Aug 12, 2020
Deals

Ligand looking to future deals around protein expression platform with Pfenex takeout

...its acquisition of Pfenex and its protein expression platform.The deal is the largest acquisition by Ligand Pharmaceuticals Inc....
...to be accretive to EPS starting next year. Ligand slipped $6.76 to $111.90 on Tuesday. Stephen Hansen Ligand Pharmaceuticals Inc. Pfenex...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...Ltd. (NSE:PEL; BSE:PEL) has P7435, a DGAT1 inhibitor, in Phase I testing for metabolic disorders. Ligand Pharmaceuticals Inc....
BioCentury | Feb 22, 2020
Product Development

COVID-19 mAb menagerie

...pathogen via recombinant proteins or pseudo-viruses” Tool companies and CDMOs are jumping into the race. Ligand Pharmaceuticals Inc....
...Tkach Tuzman, Associate Editor Vir Biotechnology Inc. AbCellera Biologics Inc. National Institutes of Health Regeneron Pharmaceuticals Inc. BARDA Ghent University WuXi Biologics Inc. Ligand Pharmaceuticals Inc. Flanders...
BioCentury | Dec 19, 2019

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

...prostate cancer. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) market Xtandi for prostate cancer. Ligand Pharmaceuticals Inc....
BioCentury | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

..."How Array Stayed Alive Long Enough to Grow Up" ). Ligand falls after RVT-1502 update Ligand Pharmaceuticals Inc....
...ciloleucel, Autologous T cell therapy against CD19 (KTE-X19, KTE-C19) Array BioPharma Inc. Gilead Sciences Inc. Hutchison China MediTech Ltd. Ligand Pharmaceuticals Inc. Pfizer...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...Co. (NYSE:LLY) 7/30 Pre $1.45 $1.50 -3% Incyte Corp. (NASDAQ:INCY) 7/30 Pre $0.48 $0.26 85% Ligand Pharmaceuticals Inc....
BioCentury | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

...Sage Therapeutics Inc. (NASDAQ:SAGE) has launched its postpartum depression therapy Zulresso brexanolone, according to partner Ligand Pharmaceuticals Inc....
...protein 1 Elizabeth S. Eaton and Sandi Wong, Staff Writers givosiran (ALN-AS1) Zulresso, brexanolone (sage-547) Alnylam Pharmaceuticals Inc. Amicus Therapeutics Inc. Ligand Pharmaceuticals Inc. PTC...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...ichthyosis in patients with Sjogren-Larsson syndrome Phase III data 2H19 Aldeyra Therapeutics Inc. (NASDAQ:ALDX) / Ligand Pharmaceuticals Inc....
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...NASDAQ:SGEN), VER250840 from Cumulus Oncology Ltd. , and V158411 from the Vernalis Research unit of Ligand Pharmaceuticals Inc....
Items per page:
1 - 10 of 850
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...to submit an NDA in China for the antibody derived from the OmniAb platform from Ligand Pharmaceuticals Inc....
BioCentury | Aug 12, 2020
Deals

Ligand looking to future deals around protein expression platform with Pfenex takeout

...its acquisition of Pfenex and its protein expression platform.The deal is the largest acquisition by Ligand Pharmaceuticals Inc....
...to be accretive to EPS starting next year. Ligand slipped $6.76 to $111.90 on Tuesday. Stephen Hansen Ligand Pharmaceuticals Inc. Pfenex...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...Ltd. (NSE:PEL; BSE:PEL) has P7435, a DGAT1 inhibitor, in Phase I testing for metabolic disorders. Ligand Pharmaceuticals Inc....
BioCentury | Feb 22, 2020
Product Development

COVID-19 mAb menagerie

...pathogen via recombinant proteins or pseudo-viruses” Tool companies and CDMOs are jumping into the race. Ligand Pharmaceuticals Inc....
...Tkach Tuzman, Associate Editor Vir Biotechnology Inc. AbCellera Biologics Inc. National Institutes of Health Regeneron Pharmaceuticals Inc. BARDA Ghent University WuXi Biologics Inc. Ligand Pharmaceuticals Inc. Flanders...
BioCentury | Dec 19, 2019

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

...prostate cancer. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) market Xtandi for prostate cancer. Ligand Pharmaceuticals Inc....
BioCentury | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

..."How Array Stayed Alive Long Enough to Grow Up" ). Ligand falls after RVT-1502 update Ligand Pharmaceuticals Inc....
...ciloleucel, Autologous T cell therapy against CD19 (KTE-X19, KTE-C19) Array BioPharma Inc. Gilead Sciences Inc. Hutchison China MediTech Ltd. Ligand Pharmaceuticals Inc. Pfizer...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...Co. (NYSE:LLY) 7/30 Pre $1.45 $1.50 -3% Incyte Corp. (NASDAQ:INCY) 7/30 Pre $0.48 $0.26 85% Ligand Pharmaceuticals Inc....
BioCentury | Jul 1, 2019
Company News

July 1 Company Quick Takes: Alnylam submits MAA for hepatic porphyria therapy; plus Sage, Amicus and PTC

...Sage Therapeutics Inc. (NASDAQ:SAGE) has launched its postpartum depression therapy Zulresso brexanolone, according to partner Ligand Pharmaceuticals Inc....
...protein 1 Elizabeth S. Eaton and Sandi Wong, Staff Writers givosiran (ALN-AS1) Zulresso, brexanolone (sage-547) Alnylam Pharmaceuticals Inc. Amicus Therapeutics Inc. Ligand Pharmaceuticals Inc. PTC...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...ichthyosis in patients with Sjogren-Larsson syndrome Phase III data 2H19 Aldeyra Therapeutics Inc. (NASDAQ:ALDX) / Ligand Pharmaceuticals Inc....
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...NASDAQ:SGEN), VER250840 from Cumulus Oncology Ltd. , and V158411 from the Vernalis Research unit of Ligand Pharmaceuticals Inc....
Items per page:
1 - 10 of 850